The Zhitong Finance App learned that Tongyuankang Pharmaceutical-B (02410) rose by more than 9% this morning. As of press release, it had risen 9.7% to HK$2.94, with a turnover of HK$9.632 million.
According to the news, Tongyuankang Pharmaceutical announced last night that Chairman, Executive Director and CEO Wu Yusheng announced that 635,000 H shares were purchased on the open market between the 8th and 10th of this month, accounting for about 0.17% of the total issued share capital, at a total cost of about HK$2.09 million. The company said that Wu Yusheng has indicated that it may continue to buy shares in the future according to market conditions. It is currently anticipated that the total amount of further shares to be purchased on this basis will not exceed HK$3 million. Wu Yusheng said that the capital to buy the shares came from his own funds. This further increase in shareholding shows our belief and full confidence in the Group's future development prospects.
At the end of last month, Tongyuankang Pharmaceutical announced that the new-generation EGFR-TKI innovative drug deuterosenitinib mesylate tablets (TY-9591 tablets) independently developed by the company has obtained approval from the China National Drug Administration (NMPA) for marketing with conditions. The indications are an adult patient with epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) replacement mutation, accompanied by locally advanced or metastatic non-small cell lung cancer (NSCLC) metastases in the central nervous system (CNS) Line therapy.